unnamed456.jpeg
Arnab Basu, Kromek chief executive Picture: Christopher Owens

Kromek nets further $5 million in ‘landmark’ deal

A technology firm behind equipment used to diagnose serious illness has secured a further $5 million as part of a “landmark” deal.

Kromek Group has received $5 million from Siemens Healthineers as part of a $37.5 million multi-year agreement to licence its advanced detector technology for use in next-generation medical imaging systems. 

The agreement supports Siemens in manufacturing SPECT scanners powered by Kromek’s cadmium zinc telluride (CZT) platform, which is developed in County Durham.

With the latest payment, Kromek has received $30 million of the total agreed value, with the remaining $7.5 million due over the next three and a half years.

Bosses say the deal is “transformational” and will provide a “robust foundation” for future growth.

The company’s detectors enable sharper, lower-dose scans for nuclear medicine imaging, supporting the diagnosis of conditions such as cancer and Alzheimer’s.

Arnab Basu, chief executive of Kromek, which is headquartered at NETPark, in Sedgefield, said: “We have continued to successfully deliver on our commitments under our landmark multi-year agreement with Siemens Healthineers, which is progressing as scheduled. 

“To date, we have received a total of $30 million, which is transformational for our business. 

“Alongside supporting the delivery of various milestones under the agreement, it will significantly strengthen our balance sheet and provide a robust foundation for sustainable growth.”

Closer to home, Kromek is also leading a Newcastle-based clinical project focused on improving breast cancer diagnosis. 

Its prototype ultra-fast molecular breast imaging scanner uses the same CZT platform to deliver faster, clearer 3D scans for patients with dense breast tissue at a significantly lower radiation dose.

The initiative brings together Newcastle Hospitals, Newcastle University and UCL, with early trials showing promising results for detecting hard-to-spot cancers and enhancing early treatment options.

Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →

Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.

Enjoy the read? Get Bdaily delivered.

Sign up to receive our daily bulletin, sent to your inbox, for free.

* Occasional offers & updates from selected Bdaily partners

Our Partners